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By using monoiodinated radioligands of both intact neuropeptide Y (NPY) and of a long C-terminal fragment, NPYtM6, 
two subtypes of binding sites, which differ in affinity and specificity, have been characterized. The Y, type of binding 
site, characterized on a human neuroblastoma cell line, MC-IXC, and a rat pheochromocytoma cell line, PC-12, binds 
NPY with a dissociation constant (&) of a few nanomolar but does not bind NPYia6. The Y2 type of binding site, 
characterized on porcine hippocampal membranes and on another human neuroblastoma cell line, SMS-MSN, is of 
higher affinity and binds both NPY and NPY iM6. None of the binding sites distinguish between NPY and the homo- 
logous peptide YY (PYY). It is concluded that NPY/PYY-binding sites occur in two subtypes which may represent two 
types of physiological receptors. 
Neuropeptide Y; Hippocampus; Brain receptor; (Neuroblastoma cell line, PC-12 cell) 
1. INTRODUCTION 
Neuropeptide Y (NPY) is an important 
regulatory peptide in both the central and 
peripheral nervous system [ 1,2]. Centrally, NPY is 
thought to be involved in regulation of food in- 
take, memory processing and circadian rhythm 
[3-61. In the periphery, NPY seems to function as 
a transmitter in sympathetic nerves where it in- 
teracts with norepinephrine mainly in the regula- 
tion of vascular tone [7-91. NPY is also found in 
non-adrenergic neurones e.g. in the gastro- 
intestinal tract [ 10,111. 
The primary structure of the 36 amino acid NPY 
has been well conserved during evolution [12]. The 
peptide belongs to the pancreatic polypeptide-fold 
(PP-fold) family of peptides, which are 
characterized by a common tertiary structure, the 
so-called PP-fold [ 131. This structural feature con- 
sists of two anti-parallel helices, an N-terminal 
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polyproline helix and a long amphipathic a-helix, 
connected by a P-turn [14]. The PP-fold is stable, 
even in dilute aqueous solution, as indicated by cir- 
cular dichroism studies [13-151. In addition to 
NPY, pancreatic polypeptide (PP), a pancreatic 
hormone [16] and peptide YY (PYY), a hormone 
from the lower intestine [17] belong to the family. 
Specific-binding sites for NPY have been 
described in membrane preparations from brain 
tissue [l&21], and in membranes from blood 
vessels [22] as well as on rat pheochromocytoma 
cells [23]. It has been suggested that in the sym- 
pathetic nervous system, two distinct subtypes of 
NPY receptors are responsible for the pre-synaptic 
and post-synaptic effects of the peptide [24]. In the 
test systems initially used, the post-junctional ef- 
fect, vasoconstriction, could only be obtained with 
the intact NPY molecule, whereas a long C- 
terminal fragment, NPY13-36, was sufficient to 
elicit pre-junctional inhibition of stimulated 
norepinephrine release [24]. However, these sub- 
types of NPY receptors were not generally ac- 
cepted, mainly because the long C-terminal 
fragment in other biological test systems was 
capable of producing vasoconstriction [21,25]. In 
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the present paper, we have used the long C- 
terminal fragment of NPY both in the labeled and 
unlabeled form to characterize two types of NPY- 
binding sites occurring on brain membranes and 
cell lines. 
2. MATERIALS AND METHODS 
2.1. Peptides 
Porcine NPY’-36 and porcine PYY’-36 were purchased from 
Peninsula (St. Helens, England). Porcine NPY’3-36 and porcine 
PYY’3-36 were custom synthesized by Ferring, Sweden. The 
peptides were characterized and quantitated by several peptide 
chemical means, among which a radioimmunoassay (using rab- 
bit antiserum no.8999) which is specific for the common C- 
terminal, amidated hexapeptide of NPY and PYY. 
2.2. Radioactive ligands 
NPY’-36 and NPY’3-36 were iodinated by Na’251 (Amer- 
sham) using the oxidative agent 1,3,4,6-tetrachloro-3a,6a- 
diphenylglycoluril (Serva) as described in detail previously for 
NPY and PP [23,26]. The radioligands were purified by reverse- 
phase high-performance liquid chromatography (HPLC) using 
a Nucleosil 300-5 Crs column, 0.4 x 25 cm, with a flow rate of 
1 ml/min at 50°C. For NPY’-36, the column was eluted 
isocratically with 35% acetonitrile in 0.1% trifluoroacetic 
acid/water, and for NPY’3-36 with 31% acetonitrile. Through 
this procedure, it was possible to prepare radioligands which 
were monoiodinated in specific positions. The radioligands 
were characterized by HPLC mapping of tryptic fragments on 
a Nucleosil Cis column (as above) eluted with a gradient of 
acetonitrile: O-15070 in 7 min, 15-20% from 7 to 22 mitt, and 
20-50% from 22 to 30 min. The column was calibrated with 
tryptic fragments of ‘cold’-iodinated NPY, and the radiolabel- 
ed fragments were further characterized with respect o mono- 
or di-iodination by HPLC of the radiolabeled amino acids after 
pronase digestion [26]. [‘Z51-Tyr36]MonoiodoNPY1-36, with a 
specific radioactivity of 1900 CVmmol, and [‘*‘I- 
Tyr36]monoiodoNPY’3-36, with a specific activity of 
1550 Ci/mmol, were used for binding experiments in the pre- 
sent study. 
2.3. Cell culture 
The human neuroblastoma cell lines MC-IXC, a subclone of 
SK-N-MC, and SMS-MSN [27], were kindly provided by Dr 
June Biedler (Sloan Kettering Memorial Institute, NY, USA) 
and PC12 cells [28], subclone 11-250, by Dr Hans Thoenen 
(Max-Planck-Institut fur Psychiatric, Martinsried, FRG). MC- 
IXC and SMS-MSN cells were grown at 5Vo COz in a 1: 1 mix- 
ture of Ham’s F-10 medium and Dulbecco’s modified Eagle’s 
medium 1885 with 15% fetal calf serum and 1% non-essential 
amino acids, 2 mM glutamine and penicillin/streptomycin 
(100 IU and 100 g/ml, respectively). PC12 cells were grown at 
101 CO2 in Dulbecco’s modified Eagle’s medium sup- 
plemented with lOolo horse serum and 5% fetal calf serum. All 
media and materials for tissue culture were from Gibco (Ux- 
bridge, England). 
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2.4. Binding experiments 
2.4.1. Cells 
As described in detail previously for PC 12 cells [23], binding 
studies with cells were performed with 25 pM of radioligand at 
37°C using triplicates of 1.2 x IO6 cells which had been prein- 
cubated for 2 days in petri wells, 6-well culture plates (Costar, 
Cambridge, MA, USA) coated with poly-Lys-Ala. The incuba- 
tion time was standardized to 60 min. although experiments 
with PC-12 cells were performed with 30 min incubations. 
2.4.2. Brain membranes 
Synaptic membranes were prepared from porcine hippocam- 
pal tissue according to the method of Gray and Wittaker [29], 
in which the PZ fraction was subfractionated on a discontinuous 
sucrose gradient and membranes from the interface between 
concentrations of 0.8 and 1.2 M sucrose were used. Binding was 
performed with 25 pM of radioligand at 37°C in 1 ml of a 
25 mM Hepes buffer, pH 7.4, containing 2.5 mM CaClz, 1 mM 
MgClz, 10 g/l bovine serum albumin and 0.5 g/l bacitracin 
with a final concentration of 200 mg of membrane protein/l. 
After 60 min, triplicates of 0.25 ml were transferred to 
polypropylene tubes, 0.4 x 4.5 cm, and the membranes were 
centrifuged through 0.2 ml of ice-cold binding buffer. The 
pellet was washed gently and the tip of the tube was cut off and 
counted. 
2.4.3. Rebinding experiments 
In order to study the degradation of the radioligands during 
incubations, the tracers were incubated with either cells or hip- 
pocampal membranes for various time periods whereafter the 
binding buffer with unbound peptide was removed and sub- 
jected to rebinding with hippocampal membranes. 
3. RESULTS 
Specific steady-state binding to hippocampal 
membranes and cells was obtained with radiola- 
beled NPY1-36 within 45 min. The hippocampal 
membranes bound 27 + 4% of the radioligand in 
the absence of cold peptide (mean f SE); and this 
was reduced to 5 f 1% (non-specific binding) in 
the presence of excess amounts of cold peptide, 
lo+ M NPY1-36. Specific and non-specific 
binding of radiolabeled NPY’-36 to the different 
cell lines were: SMS-MSN, 4.1 and 1.6%; PC-12, 
4.8 and 1.4%, and MC-IXC, 3.8 and 1.6%. 
The binding sites for NPY appeared to fall into 
two categories which differed with respect to af- 
finity and specificity. In the hippocampal mem- 
branes and the SMS-MSN cells the radiolabeled 
NPY’-36 was displaced by unlabeled NPY’-36 with 
an apparent 50% inhibitory concentration (I&J) 
of 0.5 and 0.1 nM, respectively, and by NPY13-36 
with an apparent ICSO of 2 nM in both systems 
(fig.1). In contrast, the apparent ICSO for NPY’-36 
was 5 and 6 nM in MC-IXC and PC-12 cells, 
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Fig.1. Inhibition of [‘251-Tyr36]monoiodoNPY’-36 binding by NPY, PYY and fragment 13-36 of NPY and PYY. NPY’-j6 (a), 
NPY’3-36 (o), PYY’-36 (A), and PYY’3-36 (A) were used for displacement. Experiments were performed in PC-12 cells (N = 12, 
NPY’-36; N = 6 for both PYY’-36 and NPY’3-36), in MC-IXC cells (N = 13 for NPY’-36; N = 5 for NPY’3-36), in SMS-MSN cells 
(N = 5 for all peptides), and on hippocampal membranes (N = 6 for all peptides). 
respectively; whereas NPY’3-36 in neither of these 
cell lines, not even in concentrations of 100 nM, 
significantly displaced the radiolabeled NPY’-36 
(fig.1). By using the nomenclature proposed by 
Wahlested et al. [24], the binding sites on hip- 
pocampal membranes and SMS-MSN cells, for 
which NPY’3-36 is a relatively good ligand, could 
be classified as Y2 type NPY receptors; whereas the 
binding sites on PC-12 cells and MC-IXC cells, for 
which NPY13-36 is a poor ligand, are of the Yr 
type. NPY and the homologous PYY could not be 
distinguished by the Yr and the YZ types of NPY- 
binding sites either in the intact molecular form, as 
shown in PC-12 cells, SMS-MSN cells, and on hip- 
pocampal membranes, or as the respective 13-36 
fragments as shown in the two YZ receptor systems, 
SMS-MSN cells and hippocampal membranes 
(fig. 1). 
In order to produce a specific YZ receptor 
radioligand, NPY13-36 was radiolabeled. As shown 
in fig.2, it was possible by HPLC to isolate [r2?- 
Tyr36]monoiodoNPY 13-36 from the ascending part 
of the composed peak of differently radiolabeled 
peptides. Specific steady-state binding of the 
radiolabeled NPY’3-36 was obtained within 45 min 
and maintained for 2 h in hippocampal mem- 
branes and SMS-MSN cells. The specific binding 
of monoiodinated NPY13-36 to hippocampal mem- 
branes was saturable and of high affinity as shown 
in fig.3. The linearity of Scatchard plots of the bin- 
ding experiments with [1251-Tyr36]monoiodo- 
NPY’3-36 indicates that NPY13-36 binds to a 
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Fig.2. Purification and characterization of ‘ZSl-labeled 
NPY’3-36 for receptor binding. (Left panel) The HPLC profile 
of NPY ‘3-36, iodinated as described in detail in the text, and 
purified on a Nucleosil Cts column eluted isocratically at 31% 
acetonitrile in 0.1% TFA/water; 10 1 of each fraction were 
counted. The elution position of unlabeled NPY’3-36 is 
indicated by a vertical arrow. (Righthand panels) HPLC 
mappings of radiolabeled tryptic fragments of fractions 19 and 
25 (arrowheads in the left panel); for chromatographic details 
see text. The elution positions of the radioiodinated fragments 
are indicated; [‘*‘I]Tyr-amide corresponds to [‘251]Tyr36 of
NPY. 
homogeneous population of binding sites (fig.3B). 
The dissociation constant was calculated to be 
0.15 nM and the concentration of binding sites 
485 fmol/mg membrane protein. The radiolabeled 
NPY13-36 was displaced from the hippocampal 
membranes by NPY’-36, NPY’3-36, and PYY13-36 
in a similar manner as the radiolabeled intact NPY 
molecule (fig.4). In contrast, radiolabeled 
NPY13-36 bound to PC-12 cells (shown in fig.4) 
and to MC-IXC cells in a non-specific manner on- 
ly, as it could not be displaced by unlabeled 
NPY’-36 or NPY’3-36. 
The different performance of the intact 
molecule and the long C-terminal fragment might 
reflect differences in the degradation of these 
molecules during the incubation. However, the in- 
tact molecule and the 13-36 fragment of NPY ap- 
peared to be equally stabile as judged by the ability 
of the radiolabeled species to bind to hippocampal 
membranes after being incubated with MC-IXC 
cells or SMS-MSN cells for various periods (fig.5). 
Similar results were obtained in PC-12 cells and 
with primary incubation with hippocampal mem- 
branes (data not shown). Thus, the inability of 
NPY’3-36 to bind to and its inability to displace 
Bound 
fmol/mg 
400 
J 
0 0.5 1 .o 
1 lz5 I_Tyr36 lmonoiodo-NPY ’ 3-3t nM 
Fig.3. Saturation binding of [‘251-Tyr36]monoiodoNPY’3-36 to 
porcine hippocampal membranes. The specific binding, i.e. 
total minus nonspecific binding in the presence of 10m6 M
NPY’3-36, of increasing amounts of [‘251-Tyr36]monoiodo- 
NPY’3-36 to porcine hippocampal membranes i  indicated (0). 
(Inset) Scatchard transformation of the binding data; & was 
0.15 nM and Bma, was 485 fmol/mg membrane protein. 
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Fig.4. Binding of [‘Z51-Tyr36]monoiodoNPY’3-36 to
hippocampal membranes and PC-12 cells. The binding of [‘*‘I- 
Tyr36]monoiodoNPY’3-36 to porcine hippocampal membranes 
was inhibited by NPY’-s6 (e), N = 7; by NPY’3-36 (O), N = 8; 
and by PYY’3-36 (A), N = 6. Binding of [‘251-Tyr”6]monoiodo- 
NPY’3-36 to PC-12 cells was not significantly inhibited by 
NPYt-s6, N = 4, or by NPY’3-36, N = 4. 
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Fig.5. Stability of radioligands as indicated by rebinding of 
[‘2SI-Tyr36]monoiodoNPY’-36 and [‘251-Tyr36]monoiodo- 
NPY’3-36 to hippocampal membranes. (Top pand) Rebinding 
of [‘251-Tyr36]monoiodoNPY’-36, total (o--o) and non- 
specific (o---o), and of [‘251-Tyr36]monoiodoNPY’3w36, total
(M) and non-specific binding (O---O) after exposure to 
MC-IXC cells for various periods. (Bottom panel) Rebinding 
data after primary exposure to SMS-MSN cells. 
radiolabeled NPY1-36 from cells with Yr receptors 
does not reflect rapid degradation of the C- 
terminal fragment. 
4. DISCUSSION 
Both Yi and YZ receptors accept NPY and PYY 
equally well (figs 1 and 3). Whether the hormone, 
PYY, the neuropeptide, NPY, or both act as 
physiological igands for any particular receptor is 
dependent on the actual concentration of the pep- 
tide in a specific location in relation to the affinity 
of the receptor. Thus, YZ receptors in e.g. the hip- 
pocampus, where only NPY is found, are probably 
‘NPY receptors’, whereas YZ receptors on tubular 
cells in the kidney, where no NPY innervation is 
found, may be ‘PYY receptors’, responding to cir- 
culating PYY. 
In the present paper we have, by using From the data presented in the present paper it 
monoiodinated radioligands of both the intact is not possible to establish whether the two types of 
NPY molecule and of NPY’3-36, characterized two NPY/PYY-binding sites in fact represent wo dif- 
subtypes of NPY-binding sites, which differ in af- ferent molecular species of receptors or just two 
finity as well as specificity. The Yr type of NPY different states of one receptor. However, as the 
receptors, which are found e.g. on the human genes for receptors for e.g. biogenic amines are be- 
neuroblastoma cell line, MC-IXC, and the rat ing cloned, it appears that receptors are found in 
pheochromocytoma cell line, PC-12, binds NPY even more variant forms than those known from 
with a dissociation constant (&) of a few pharmacological experiments [32]. The presence of 
nanomolar but does not bind the long C-terminal these NPY receptor subtypes on cell lines offers 
fragment. The YZ type of NPY receptors binds 
NPY with a dissociation constant in the sub- 
nanomolar range and more importantly, NPY13-36 
is a relatively good ligand for these receptors 
(fig.3). These two types of binding sites could 
represent the biochemical equivalents to the two 
types of biological receptors described by 
Wahlestedt et al. [24]. 
YZ receptors are found pre-junctionally on sym- 
pathetic nerves [24], whereas the post-junctional 
receptors are apparently of either the Yi or the Y2 
types, as described mainly on the basis of 
biological responses [9,13,14,18]. In the central 
nervous system, the Yt type of receptor seems to be 
predominating. The receptors originally described 
by Unden et al. [17] in the rat cortex have an affini- 
ty and specificity similar to those of the porcine 
hippocampal YZ receptors of the present study 
[26,30]. The NPY (Yz) receptors in the hippocam- 
pus have been classified as being pre-junctional on 
the basis of electrophysiological data [31]. It is 
likely that Yi receptors are also found in certain 
areas of the central nervous system, because unlike 
intact NPY, the fragment, NPY13-36, cannot 
evoke e.g. the centrally mediated lowering .of 
blood pressure and the stimulation of feeding 
behaviour (Fuxe, K. and Kalra, S.P., personal 
communications). 
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special possibilities in respect of molecular 
characterization of the receptors and characteriza- 
tion of secondary messengers systems involved in 
their action. 
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